A record 621 people died of drug overdoses in San Francisco so far this year, a staggering number that far outpaces the 173 deaths from COVID-19 the city has seen thus far.
The crisis fueled by the powerful painkiller fentanyl could have been far worse if it wasn’t for the nearly 3,000 times Narcan was used from January to the beginning of November to save someone from the brink of death, the San Francisco Chronicle reported Saturday.
The data reflects the number of times people report using Narcan to the Drug Overdose Prevention and Education Project, a city-funded program that coordinates San Francisco’s response to overdose, or return to refill their supply. Officials at the DOPE Project said that since the numbers are self-reported, they are probably a major undercount.
Last year, 441 people died of drug overdoses—a 70% increase from 2018—and 2,610 potential overdoses were prevented by Narcan, a medication commonly sprayed up the nose to reverse an opioid overdose, according to data from the city Medical Examiner’s office and the DOPE Project.
The crisis is deepening because fentanyl, which can be 50 to 100 times more potent than morphine, flooded the city’s drug supply, the newspaper said. Moreover, the coronavirus pandemic has disrupted city services like housing and treatment, and left many people who rely on others to help save them if they overdose to use alone.
While nearly 40% of the deaths occurred in the Tenderloin and South of Market neighborhoods near downtown, city data showed the epidemic has touched every part of the city. Many people overdosed in low-income apartment buildings and in city-funded hotel rooms for the homeless. Others died on sidewalks, in alleyways and parks around the city.
© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Overdose deaths far outpace COVID-19 deaths in San Francisco (2020, December 20)
retrieved 21 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.